Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
ALBUQUERQUE, NM and SAN DIEGO, CA, Sept. 11, 2017 -- Exagen Diagnostics Inc. (“Exagen”), a commercial stage specialty diagnostic company and exclusive home of AVISE testing, announced today that it has completed two significant capitalization events.
|
|||
The company has entered into a debt financing agreement with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”), to provide Exagen Diagnostics with up to $25 million in term loans. Combined with more than $23 million raised in a Series F equity offering earlier this year, Exagen Diagnostics has raised over $48 million this year to accelerate the commercialization of the company’s proprietary Cell Bound Complement Activation Products (CB-CAPs) technology.
"This funding is a testament to the value we bring to the challenging and costly area of autoimmune disease. Through our unique diagnostic, prognostic and drug monitoring tests we facilitate timely and accurate decision-making so providers can get patients on the road to wellness. This strong capital position will also assists us in maintaining our impressive growth trajectory as we prepare to commercialize our pipeline products and carryout our clinical utility studies“ stated Ron Rocca, Chief Executive Officer of Exagen Diagnostics.
About Exagen Diagnostics
Exagen Diagnostics, Inc. is a College of American Pathologists (CAP) accredited and CLIA certified rheumatology specialty laboratory that focuses on the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of autoimmune connective tissue diseases (CTD). Its groundbreaking solutions address the full continuum of care with tools designed and clinically shown to help physicians deliver accurate, early diagnosis and optimized therapy. For more information, visit www.AviseTest.com
About Innovatus Capital Partners
Innovatus Capital Partners, LLC, is an independent adviser and portfolio management firm with ~$1.7 billion in assets under management. The firm adheres to an investment strategy that identifies distressed, disruptive and growth opportunities in the less obvious market segments across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. Further information can be found at innovatuscp.com.
Exagen, AVISE, and the Exagen and AVISE logos are registered trademarks of Exagen Diagnostics Inc.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/028ff7c0-cb1a-491e-a969-83f2ca321206
Kamal Adawi Exagen Diagnostics, Inc. 760-477-5514 [email protected]
